Earnings Feed
Start Free
Traws Pharma, Inc.·4

Apr 8, 2:47 PM ET

Parker Charles Nolan 4

4 · Traws Pharma, Inc. · Filed Apr 8, 2026

Research Summary

AI-generated summary of this filing

Updated

Traws Pharma (TRAW) CFO Parker Nolan Receives 213,914 Awards

What Happened Parker Charles Nolan, Chief Financial Officer of Traws Pharma, received a series of equity awards totaling 213,914 units across four grants. The awards (reported as acquisitions at $0.00) consist of 15,393 restricted stock units (RSUs) and three stock-option grants totaling 198,521 option units (32,406; 61,571; 104,544). These were grants/awards (non-cash compensation), not open-market purchases or sales.

Key Details

  • Transaction dates and amounts:
    • 2025-12-12: 15,393 RSUs granted at $0.00 (F1).
    • 2025-10-12: 32,406 stock options granted at $0.00 (F2).
    • 2025-12-12: 61,571 stock options granted at $0.00 (F3).
    • 2026-03-08: 104,544 stock options granted at $0.00 (F4).
  • Total awards reported: 213,914 units.
  • Vesting/terms: RSUs convert one-for-one into common shares and, per footnotes, each stock-option award vests 100% on the first anniversary of its grant date. Awards were approved by the issuer’s compensation committee (independent directors).
  • Shares owned after transaction: not disclosed in the filing.
  • Filing timeliness: Form filed 2026-04-08; the earliest reported grant was 2025-10-12 — the filing appears late relative to the transaction dates.

Context

  • RSUs and stock options are compensation vehicles: RSUs convert to shares on vesting; options give the right to buy shares subject to exercise and any applicable strike price. These awards are not immediate market purchases or sales and will only affect outstanding common stock if/when RSUs vest or options are exercised.
  • Because the filing is a grants/awards report rather than a purchase, it signals compensation activity rather than a direct insider buy or sell of shares.

Insider Transaction Report

Form 4
Period: 2025-10-12
Traws Pharma, Inc.TRAW
Parker Charles Nolan
Chief Financial Officer
Transactions
  • Award

    Common Stock

    [F1]
    2025-12-12+15,393→ 15,393 total
  • Award

    Stock Option (right to buy)

    [F2]
    2025-10-12+32,406→ 32,406 total
    Exercise: $3.01From: 2026-10-12Exp: 2035-10-12→ Common Stock (32,406 underlying)
  • Award

    Stock Option (right to buy)

    [F3]
    2025-12-12+61,571→ 61,571 total
    Exercise: $2.33From: 2026-12-12Exp: 2035-12-12→ Common Stock (61,571 underlying)
  • Award

    Stock Option (right to buy)

    [F4]
    2026-03-08+104,544→ 104,544 total
    Exercise: $1.60From: 2027-03-08Exp: 2036-03-08→ Common Stock (104,544 underlying)
Footnotes (4)
  • [F1]Represents an award of restricted stock units that will vest 100% on the first anniversary of the grant date. Each restricted stock unit will convert into shares of common stock on a one-for-one basis.
  • [F2]Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.
  • [F3]Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.
  • [F4]Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.
Signature
/s/ Charles N. Parker|2026-04-08

Documents

1 file
  • 4
    form4-04082026_060446.xmlPrimary